Stryker Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYK research report →
Range $309 – $407
Price Chart
About the company
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions.
- CEO
- Kevin A. Lobo
- IPO
- 1980
- Employees
- 56,000
- HQ
- Portage, MI, US
AI snapshot
Six angles, distilled from the data.
SYK is still in a longer-term uptrend, but the stock has slipped below its 200-day average after a strong run toward the upper end of its 52-week range. The setup is a consolidation phase rather than a breakdown, with the 50-day average still above the 200-day and the shares well off the yearly low.
Street sentiment stays constructive, with a Buy consensus and a $356.69 average target versus a $317.54 last close. Recent calls have turned more cautious, with several target cuts and one downgrade to Hold after guidance and supply-chain concerns, but the broader rating mix still leans positive.
The latest quarter was a small miss, with EPS of $3.52 versus $3.56 expected, after a stronger 6.6% beat in the prior period. Analysts still model sharp forward EPS growth, so shareholders should watch whether management can reaccelerate margins and restore the beat pattern.
Recent insider activity leans negative because of one very large director sale cluster, while the officer-level filings look routine and low-signal. The sales total 6 transactions from Ronda E. Stryker on 2026-11-06, while CFO-related and controller filings appear to be administrative or non-discretionary in nature.
Profitability remains solid, with a 23.97% operating margin, 13.78% net margin, and 16.02% ROE. Revenue grew 7.6% year over year, but earnings fell 11.7%, so the key question is whether top-line strength can translate back into faster bottom-line growth.
SYK still screens as a premium medical-device name, supported by strong margins and a 4.91% free-cash-flow yield. Relative to peers, the market is paying for quality and scale, but the recent guidance reset has narrowed the valuation cushion.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $118.01B
- P/E
- 33.60
- Fwd P/E
- 20.90
- PEG
- 1.49
- P/S
- 4.60
- P/B
- 5.17
- EV/EBITDA
- 20.09
- Div Yield
- 1.11%
- Gross Margin
- 65.52%
- Op Margin
- 21.25%
- Net Margin
- 13.78%
- ROE
- 15.61%
- ROIC
- 9.50%
Latest fiscal year · YoY change
- Revenue
- $25.12B+11.2%
- Gross Profit
- $16.07B+10.5%
- Op Income
- $4.89B
- Net Income
- $3.25B+8.5%
- EPS
- $8.49+8.0%
- OCF Growth
- +18.9%
- FCF Growth
- +22.8%
- 52W High
- $389.33
- 52W Low
- $267.00
- 50D MA
- $294.94
- 200D MA
- $320.93
- Beta
- 0.78
- RSI (14)
- 52
- Avg Volume
- 2.94M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Stryker posted 7.7% organic growth and 10.3% EPS growth in Q3, but cut full-year guidance as hip/knee and peripheral vascular trends softened more than expected.· October 29, 2026
- Q3 organic sales grew 7.7%; adjusted EPS was $3.52, up 10.3% year over year.
- Adjusted gross margin improved to 65.4% and adjusted operating margin rose to 26.2%, both helped by efficiencies and expense discipline.
- Orthopaedics grew 5.9% organically, but management said the hip and knee market slowed and Stryker’s win rate was below its historical pace.
- Peripheral Vascular improved sequentially, helped by a one-time China JV revenue benefit, while supply disruption was easing.
- Full-year guidance was cut to 6.5% to 7% organic sales growth and $14.80 to $14.90 adjusted EPS.
Organic sales grew 7.7% in Q3, with MedSurg and Neurotechnology up 9.1% and Orthopaedics up 5.9%. Adjusted EPS was $3.52, up 10.3% from the prior year. Adjusted gross margin was 65.4%, up 40 basis points year over year, and adjusted operating margin was 26.2%, up 60 basis points. On cash, Stryker ended the quarter with approximately $3.3 billion of cash and cash equivalents and year-to-date cash from operations of $3.3 billion, up approximately 14%. For the full year, management now expects organic net sales growth of 6.5% to 7% and adjusted EPS of $14.80 to $14.90. They also now expect adjusted other income and expense of approximately $400 million, and a full-year adjusted tax rate of 15.5% to 16%.
Kevin Lobo said the quarter was solid overall but below expectations, driven mainly by a slowdown in hips and knees and challenges in peripheral vascular. He emphasized that the orthopaedics softness appeared to be more market-related than competitive share loss, and said the company still sees long-term attractiveness in large joint reconstruction. He also highlighted a strong innovation pipeline, including Mako-related launches, a future power hip impaction solution, and the CMR Surgical partnership as part of Stryker’s broader growth strategy.
Preston Wells said Q3’s EPS outperformance came from gross margin expansion, operational efficiencies, and disciplined spending. He cited 65.4% adjusted gross margin, 26.2% adjusted operating margin, $91 million of adjusted other income and expense, and $3.3 billion of year-to-date operating cash flow. He said the updated outlook reflects softer hip and knee procedure trends, lingering peripheral vascular supply constraints, and a more cautious view on capital equipment execution, while still expecting margin expansion and expense discipline to support EPS.
Analysts focused on whether the orthopaedics slowdown was market-driven or share loss, and management said hip and knee market growth was around 2.5% this year and that the slowdown became clearer only after SAP-related order-entry delays and the cyber incident obscured trends. They also pressed on fourth-quarter growth, and management pointed to trauma and extremities, medical, and instruments as offsets to softer ortho and vascular areas. On 2027, management would not give formal guidance but said it expects to perform at the high end of its markets and reiterated that capital demand remains strong.
The positive read is that Stryker still delivered 7.7% organic growth and double-digit EPS growth despite the drag from hips/knees and vascular. Management described the innovation pipeline as strong, with multiple upcoming launches and continued strong capital demand, and they said several businesses — especially MedSurg, trauma and extremities, and Smart Care — remain strong or improving.
The main risks are a slower-than-expected hip and knee market, weaker-than-historical share capture in orthopaedics, and lingering peripheral vascular supply disruptions. Management also flagged execution risk around capital sales and said they are still trying to understand how much of the ortho slowdown is temporary versus a broader market reset.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.8%
- Shares Outstanding
- 380.69M
- Float Shares
- 345.81M
of shares held by institutions
2,341 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for SYK, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Thomas KeanHouse · NJ07 | Sell | Oct 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 7, 26 | Filing → |
| Thomas KeanHouse · NJ07 | Sell | Sep 30, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 25, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| Thomas KeanHouse · NJ07 | Sell | Jul 22, 26 | Filing → |
| Alan ArmstrongSenate | Sell | Mar 27, 26 | Filing → |
| Thomas KeanHouse · NJ07 | Sell | Jun 2, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Apr 13, 26 | Filing → |
| Thomas KeanHouse · NJ07 | Sell | Jan 23, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Oct 16, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 33.91M | ▲ 133.89K |
| Blackrock, Inc. | 27.12M | ▼ 295.94K |
| Vanguard Capital Management LLC | 22.72M | ▲ 183.44K |
| State Street Corp | 15.80M | ▲ 266.99K |
| Greenleaf Trust | 15.16M | ▼ 72.61K |
| Jpmorgan Chase & Co | 12.28M | ▼ 4.98M |
| Wellington Management Group Llp | 10.02M | ▲ 1.86M |
| Geode Capital Management, LLC | 8.01M | ▲ 186.10K |
| Vanguard Portfolio Management LLC | 7.88M | ▼ 297.17K |
| Price T Rowe Associates Inc | 7.23M | ▼ 4.69M |
| Morgan Stanley | 5.14M | ▼ 821.09K |
| Norges Bank | 4.89M | ▲ 4.89M |
Held by 2,151 ETFs
Biggest fund positions in SYK by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | STRYKER RONDA E | sell | 33,466 |
| Nov 6, 26 | STRYKER RONDA E | sell | 131,707 |
| Nov 6, 26 | STRYKER RONDA E | sell | 142,794 |
| Nov 6, 26 | STRYKER RONDA E | sell | 149,357 |
| Nov 6, 26 | STRYKER RONDA E | sell | 82,089 |
| Nov 6, 26 | STRYKER RONDA E | sell | 10,587 |
| Sep 24, 26 | Wells Preston Wendell | other | 109 |
| Jul 17, 26 | Wells Preston Wendell | other | 1,776.804 |
| Sep 22, 26 | Wells Preston Wendell | other | 962 |
| Sep 1, 26 | Baculik Emily Kay | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SYK coverage
Recent articles, reports, and earnings notes.

Stryker (SYK): Mako Growth Supports a Buy
Stryker posted 7.7% organic sales growth and 10.3% adjusted EPS growth in Q3, with Mako and broad segment momentum supporting a Buy rating despite a rich valuation.

Stryker Corporation (SYK) rises 5.1% after earnings reset
Stryker Corporation (SYK) rises after a sharp post-earnings selloff, helped by above-average trading volume and rebound buying. The move follows a Q3 miss and lower full-year guidance, so investors are weighing whether the stock is stabilizing or just bouncing.

Stryker Corporation (SYK) falls 11.7% after guidance cut
Stryker Corporation (SYK) falls sharply after hours after reporting solid Q3 results but trimming full-year guidance. The medical-device giant still posted growth, yet investors focused on the lower outlook, premium valuation, and earnings quality concerns.
Want a deeper read on SYK?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Advisors Asset Management Inc. Purchases 91,651 Shares of Stryker Corporation $SYK
defenseworld.net · Nov 20
Stryker Sticks to Growth Goals Despite Cyberattack and Slower Orthopedic Market
marketbeat.com · Nov 19
226,075 Stryker Corporation $SYK Shares Sold by Aberdeen Group plc
defenseworld.net · Nov 18
Stryker Corporation (SYK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
GEHC or SYK: Which Is the Better Value Stock Right Now?
zacks.com · Nov 16
Stryker announces intention to nominate Jim Davis to board of directors
globenewswire.com · Nov 9
Stryker Corporation $SYK Stock: Commonwealth Equity Services LLC Trims Position
defenseworld.net · Nov 9
Stryker Corporation $SYK Shares Sold by Chicago Partners Investment Group LLC
defenseworld.net · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 18, 2026 · Live quote · Not investment advice